INGN-251

N/A

Report date: 2024/12/06 10:45:02

Base Information

Drug NameINGN-251
Drug Alias NameAdenoviral-PTENAd-PTENINGN-251
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN stimulants
TargetsPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
Therapy Area/IndicationsCardiovascular DiseasesUrogenital NeoplasmsBrain Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCancer Research Technology
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCancer Research TechnologyTexas Heart InstituteIntrogen Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsCardiovascular DiseasesUrogenital NeoplasmsBrain Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A